Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma

Yu Qian
Jing-Wen Wang
Yu-Fang Xiao-Dong Yuan
Yu-Chen Fan
Shuai Gao
Kai Wang

Corresponding Author: Kai Wang, e-mail: wangdoc876@126.com, wangdoc2010@163.com

Source of support: This work was supported by the Key Project of the Chinese Ministry of Science and Technology (2017ZX10202202, 2018ZX10302206), the National Natural Science Foundation of China (81970522), and the Key Research and Development Project of Shandong Province (2019GSF108023)

Background: Alpha-fetoprotein (AFP) is widely used to screen for hepatocellular carcinoma (HCC). However, the use of this biomarker has been challenged due to its low sensitivity and high rate of false negatives. In this study, we evaluated the diagnostic capability of cyclin D2 (CCND2) promoter methylation in patients with HCC related to hepatitis B virus (HBV).

Material/Methods: Using methylation-specific PCR and quantitative real-time PCR, we measured methylation status and mRNA levels of CCND2 in plasma and peripheral blood mononuclear cells (PBMCs) from 275 subjects: 75 patients with chronic hepatitis B (CHB), 47 with liver cirrhosis (LC), 118 with HCC, and 35 healthy controls (HCs).

Results: The methylation rate of the CCND2 promoter was significantly higher in HCC patients than in patients without HCC (P<0.001). Furthermore, advanced HCC (TNM III/IV) was associated with a significantly higher frequency of CCND2 methylation and lower CCND2 mRNA levels than early-stage disease (TNM I/II; P<0.05). Combined measurement of CCND2 methylation and AFP yielded significantly higher sensitivity and area under the curve (AUC) than AFP alone in distinguishing patients with HCC from subjects with LC and CHB (P<0.001).

Conclusions: CCND2 methylation may be useful for predicting HCC progression. In addition, combined measurement of CCND2 methylation and AFP could serve as a non-invasive diagnostic marker for patients with HBV-related HCC.

MeSH Keywords: Carcinoma, Hepatocellular • Cyclin D2 • Diagnosis • DNA Methylation

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/927444
**Background**

Hepatocellular carcinoma (HCC), which constitutes the majority of liver cancers, is the second most common cause of death from cancer around the world [1,2]. In China, HCC is mainly caused by chronic hepatitis B virus (HBV) infection [3]. Although a multitude of diagnostic and therapeutic modalities have been developed for HCC, the long-term prognosis remains poor, and 5 year survival rates are low [4]. A combination of imaging technologies such as ultrasonography (US) and determination of alpha-fetoprotein (AFP) levels is the most widely used method for detecting HCC. However, several studies have shown that low sensitivity and high rates of both false negatives and false positives limit the wide application of serum AFP levels as a marker [5,6]. Farinati et al. reported that only 54% of patients with HCC had abnormal serum AFP levels in a large multicentric survey [7]. AFP has also been questioned for its low specificity, because elevated AFP levels are also found in pregnant women and in patients with active hepatitis and embryonic carcinomas [8]. US-based detection is affected by several factors, including the professional expertise of operators, the physical status of the patient, the presence or absence of cirrhosis, and tumor size [9]. A previous study demonstrated that US alone has a sensitivity of 32% for the diagnosis of early-stage HCC [10]. In addition, US cannot be used to visualize adequately the liver in patients with a nodular liver and does not have the accuracy to distinguish HCC from other lesions [11,12]. Collectively, these parameters determine whether US can effectively detect HCC at the early stage. Potential alternative imaging modalities are unsuitable, as computed tomography (CT) scans and magnetic resonance imaging (MRI) cannot detect small HCC lesions [13]. Hence, effective and non-invasive biomarkers for diagnosis of HCC are urgently required.

DNA methylation plays crucial roles in the progression of several types of human cancer [14,15]. Moreover, changes in DNA methylation patterns are frequently observed in the early stages of disease; for example, Zhang et al. reported that altered DNA methylation could be detected 1–9 years before HCC itself [16]. Several genes have been implicated in the disease stage and clinical outcome of HCC, including APC [17], P15 [18], IGFBP7 [19], and GSTP1 [17,20]. Together, these findings suggest that assessment of DNA methylation represents a feasible approach for early diagnosis and prognostic evaluation of HCC.

**Cyclin D2 (CCND2)** regulates cell-cycle progression [21] and inhibits cell growth. Accordingly, CCND2 levels are elevated in normal human cells under growth arrest. Aberrant expression of CCND2 affects cell-cycle progression, suggesting that CCND2 has an additional function that maintains the non-proliferative state [22–24]. This effect can be relieved by the inhibition of CCND2 transcription by hypermethylation of the promoter, which frequently occurs in HCC [25]. Based on these observations, we used methylation-specific PCR (MSP) to detect the methylation status of the CCND2 promoter in both plasma and peripheral blood mononuclear cells (PBMCs). We then assessed the value of CCND2 promoter methylation as a non-invasive method for diagnosing patients with HBV-associated HCC.

**Material and Methods**

**Patients and controls**

A total of 118 patients with HCC, 47 with liver cirrhosis (LC), 75 with chronic hepatitis B (CHB), and 35 healthy controls (HCs) were recruited in the Department of Hepatology, Qilu Hospital of Shandong University, from March 2018 to December 2019. All patients were HBsAg-positive. Figure 1 depicts the selection...
process. The Ethics Committee of Qilu Hospital of Shandong University approved the study protocol, and informed consent was obtained from all participants prior to the study.

**DNA extraction from plasma and PBMCs**

Citrate-anticoagulated peripheral blood (5 mL) was collected from all subjects. DNA was extracted from 400 μL plasma using the QIAamp DNA Blood Mini Kit (Qiagen, Mainz, Germany) and stored at −20°C until use. After centrifugation on a Ficoll-Paque Plus density gradient (GE Healthcare, Uppsala, Sweden), PBMCs were collected from the interface and washed 3 times with phosphate-buffered saline. Genomic DNA was extracted from PBMCs using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Extracted DNA was eluted in 200 μL sterile water and stored at −20°C until use.

**Sodium bisulfite modification and MSP**

Extracted DNA was modified using the EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA, USA). Treatment with bisulfite converts unmethylated cytosine residues to uracil but does not affect methylated cytosine residues. Modified DNA was dissolved at a final volume of 20 μL and stored at −20°C until use. Bisulfite-modified DNA was amplified using methylated and unmethylated primers specific for the CCND2 promoter. The primer pairs used for MSP analysis of CCND2 were described previously [26].

Methylated sequence (276 bp PCR product): forward, 5'-TACGTTTAGGTGCATCG-3'; reverse, 5'-CGAATATCTACGCTAAACG-3'.

Unmethylated sequence (222 bp PCR product): forward, 5'-GTAGTTGATGTGTTGATG-3'; reverse, 5'-TAAAATCCACAAACACATCA-3'.

The MSP reaction mixture had a volume of 25 μL as follows: 10.5 μL nuclease-free water, 12.5 μL PreMix Taq (Zymo Research, Irvine, CA, USA), 0.5 μL of each primer (10 μmol/L), and 1 μL bisulfite-treated DNA. Touchdown PCR conditions were as follows: 95°C for 5 min; ten cycles of 95°C for 30 s and 72°C for 45 s; and 30 cycles of 95°C for 30 s, 45°C for 30 s, and 72°C for 45 s; and a final extension step at 72°C for 5 min. Without DNA was used as a negative control. PCR products (7 μL) were electrophoresed on 2% agarose gels and visualized under UV illumination after staining with Gel Red (Biotium, Fremont, CA, USA).

**RNA extraction from PBMCs and quantitative real-time PCR (qRT-PCR)**

RNA was extracted from PBMCs by the phenol–chloroform–iso-propanol method. Total RNA was resuspended in 20 μL RNase-free water. Subsequently, RNA was converted into cDNA using the PrimeScript RT Reagent Kit (Takara, Shiga, Japan).

Expression of CCND2 mRNA was detected by qRT-PCR on an Agilent Technologies Stratagene Mx3005P (Stratagene, La Jolla, CA, USA) using SYBR Green PCR Mix (Takara, Shiga, Japan). ACTB (encoding β-actin) was used as an endogenous control. The primer pairs used for qRT-PCR analysis of CCND2 [25] and ACTB [19] were described previously. qRT-PCR was performed as follows: initial denaturation at 95°C for 30 s, followed by 40 cycles of 95°C for 5 s, 60°C for 30 s, 72°C for 30 s, 65°C for 15 s, and 40°C for 30 s. mRNA levels were calculated using the comparative (2−ΔΔCt) method.

**Statistical analysis**

All data were analyzed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). The Mann-Whitney U-test was used to compare CCND2 mRNA levels between the HCC group and other groups, and Spearman’s rank correlation was used to assess correlations with clinical features. Differences in CCND2 methylation frequency between different groups were compared using the Chi-square test. The association between CCND2 promoter methylation status in HCC patients and clinicopathological parameters was analyzed using the Chi-square test. The diagnostic value of using CCND2 promoter methylation for distinguishing HCC from LC and CHB was assessed based on the area under the receiver operating characteristic curve (AUC). P<0.05 was considered to be statistically significant.

**Results**

**General characteristics**

Clinicopathological characteristics of the participants are provided in Table 1.

**CCND2 mRNA Levels in PBMCs of HCC**

CCND2 mRNA levels were significantly lower in HCC patients than in LC patients (P<0.001), CHB patients (P<0.001), and HCs (P<0.001; Figure 2A). However, there were no significant differences in CCND2 mRNA levels between LC patients, CHB patients, and HCs (P>0.05, respectively).

Moreover, HCC patients with advanced disease (TNM stage III/IV) had significantly lower CCND2 mRNA levels than patients with early-stage disease (TNM I/II; P=0.030; Figure 2B). CCND2 mRNA levels in the HCC group exhibited no significant relationship with age, HBsAg, gender, smoking status, alcohol use, AFP, tumor number, tumor size, vascular invasion, or CTP staging (Figure 2C–2L).
Table 1. Characterization of the study participants.

| Variable                  | HCC group (n=118) | LC group (n=47) | CHB group (n=75) | HC group (n=35) |
|---------------------------|-------------------|-----------------|-----------------|-----------------|
| Age (years)               | 54 (49–62)        | 52 (42–60)      | 50 (40–57)      | 47 (39–55)      |
| Male gender, n (%)        | 87 (73.73)        | 35 (74.47)      | 52 (69.33)      | 23 (65.71)      |
| HBeAg+, n (%)             | 43 (36.44)        | 22 (46.81)      | 41 (54.67)      | NA              |
| ALT (U/L)                 | 37.50 (24.00–69.50) | 51.00 (30.00–98.00) | 101.00 (57.00–227.00) | NA              |
| AST (U/L)                 | 46.00 (30.75–99.25) | 62.00 (36.00–121.00) | 61.00 (42.00–121.00) | NA              |
| TBIL (μmol/L)             | 18.35 (13.93–37.93) | 22.50 (15.40–46.40) | 20.00 (11.80–49.90) | NA              |
| ALB (g/L)                 | 39.90 (33.98–43.13) | 40.80 (34.90–44.60) | 41.60 (37.50–44.90) | NA              |
| PT-INR                    | 1.10 (1.02–1.20)  | 1.12 (1.05–1.21) | 1.11 (1.05–1.21) | NA              |
| AFP (ng/mL)               | 36.41 (4.98–317.78) | 12.90 (9.18–115.20) | 15.91 (6.21–77.98) | NA              |
| Methylation in PBMCs/plasma, n (%) | 55 (46.61)/52 (44.07) | 8 (17.02)/5 (10.64) | 8 (10.67)/7 (9.33) | 4 (11.43)/2 (5.71) |

HCC – hepatocellular carcinoma; LC – liver cirrhosis; CHB – chronic hepatitis B; HC – healthy controls; ALT – alanine aminotransferase; AST – aspartate aminotransferase; TBIL – total bilirubin; ALB – albumin; PT-INR – prothrombin time-international normalized ratio; AFP – alpha-fetoprotein; PBMCs – peripheral blood mononuclear cells; NA – not available.

Methylation frequency of CCND2 and its correlation with gene transcription

The frequency of CCND2 promoter methylation was significantly higher in HCC patients (55/118, 46.61% in PBMCs; 52/118, 44.07% in plasma) than in LC patients (8/47, 17.02% in PBMCs; 5/47, 10.64% in plasma; P<0.001), CHB patients (8/75, 10.67% in PBMCs; 7/75, 9.33% in plasma; P<0.001), and HCs (4/35, 11.43% in PBMCs; 2/35, 5.71% in plasma; P<0.001; Figure 3A, 3B). However, CCND2 methylation frequencies did not differ significantly between LC patients, CHB patients, and HCs (P>0.05, respectively).

To determine whether altered promoter methylation could affect CCND2 transcription, we compared CCND2 mRNA levels in subjects with and without promoter methylation. In the HCC group, the level of CCND2 mRNA was significantly lower in methylated subjects than in unmethylated subjects (P=0.041; Figure 3C). These data support our hypothesis. Figure 3D shows a representative result of agarose gel electrophoresis.

Association between CCND2 promoter methylation and HCC progression

Table 2 shows that the methylation frequency of the CCND2 promoter in HCC patients was significantly higher in HCC patients with vascular invasion than in those without vascular invasion (P=0.0012 in PBMCs; P=0.008 in plasma). In addition, CCND2 promoter hypermethylation was more common in HCC patients with advanced disease (TNM III/IV) than in those with early-stage disease (TNM I/II; P=0.004 in PBMCs; P=0.001 in plasma). The CCND2 methylation rate increased gradually with TNM stage (Table 3). Together, these results reveal that CCND2 methylation is more frequent in advanced-stage HCC patients. We found no significant correlations between CCND2 methylation status and other parameters.

Diagnostic utility of CCND2 promoter methylation and AFP level

For discrimination of HCC from LC, CCND2 promoter methylation had a sensitivity of 46.61% in PBMCs and 44.07% in plasma, and a specificity of 82.98% in PBMCs and 89.36% in plasma. For discrimination of HCC from CHB, CCND2 promoter methylation had a sensitivity of 46.61% in PBMCs and 44.07% in plasma, and a specificity of 89.33% in PBMCs and 90.67% in plasma (Table 4). Figure 4A and 4B show that the AUC of combined measurement of CCND2 promoter methylation and AFP level was significantly higher than that of AFP alone (0.540 in PBMCs, P<0.001; 0.571 in plasma, P<0.001) in discriminating HCC from LC. The AUC of combined measurement was also significantly higher than that of AFP alone (0.724 vs. 0.571 in PBMCs, P<0.001; 0.698 vs. 0.540 in plasma, P<0.001) in discriminating HCC from CHB (Figure 4C, 4D).

Next, we compared the diagnostic value of combined measurement of CCND2 methylation and AFP with that of AFP alone for discriminating HCC from LC. As shown in Figure 5, the HCC detection rate in the CCND2-methylated group was significantly higher than that in the CCND2-unmethylated group,
regardless of whether the AFP level was ≤20 ng/mL or >20 ng/mL ($\chi^2=14.246, P<0.001$, AFP ≤20 ng/mL; $\chi^2=5.499, P=0.018$, AFP >20 ng/mL). We defined AFP >20 ng/mL or the presence of CCND2 methylation as positive. Table 4 revealed that for discrimination of HCC from LC, measurement of CCND2 methylation plus AFP had a sensitivity of 82.20% (97/118) in PBMCs and 81.36% (96/118) in plasma; a specificity of 57.45% (27/47) in both PBMCs and plasma; a PPV of 82.91% (97/117) in PBMCs and 81.36% (96/118) in plasma; and a negative predictive value (NPV) of 56.25% (27/48) in PBMCs and 55.10% (27/49) in plasma. Notably, the sensitivity of combined measurement was significantly higher than that of AFP alone ($P<0.001$). Similarly, for discriminating HCC from CHB, combined measurement had higher sensitivity (82.20% vs. 57.63% in PBMCs, $P<0.001$; 81.36% vs. 76.37% in plasma, $P<0.001$) and NPV (69.12% vs. 48.98% in PBMCs, $P=0.010$; 68.12% vs. 48.98% in plasma, $P=0.014$) than AFP alone (Table 4).

**Discussion**

CCND2 promoter methylation occurs in multiple types of cancer, including breast, gastric, and prostate cancers [26-28]. In this study, we evaluated the potential utility of CCND2 promoter methylation in PBMCs and plasma as a non-invasive biomarker for diagnosis of HBV-associated HCC. Our results...
revealed that expression of CCND2 mRNA was significantly lower in patients with HCC than in patients with LC, CHB, and HCs; moreover, CCND2 methylation frequency was significantly higher in HCC patients than in other groups. In patients with HBV-related HCC, CCND2 promoter methylation was significantly associated with vascular invasion and negatively correlated with TNM stage. Furthermore, we showed that combined measurement of CCND2 methylation status and serum AFP increased the ability to distinguish HBV-associated HCC from LC and CHB. Therefore, our findings indicate that CCND2 promoter methylation represents a potentially useful non-invasive biomarker for diagnosis of HBV-related HCC.

CCND2 is involved in cell-cycle regulation, in which its critical function involves the formation of a complex with subunits of CDK6 and CDK4, resulting in phosphorylation of retinoblastoma protein (RB) [21,26]. Overexpression of CCND2 is correlated with progression and poor prognosis of several cancers, indicating that CCND2 should be considered as a proto-oncogene [29,30]. However, silencing of CCND2 expression by promoter methylation is associated with cancer progression, indicating that CCND2 expression is inhibited by aberrant promoter methylation; thus it would be reasonable to consider CCND2 as a tumor suppressor gene [31,32]. In prostate cancer, elevated methylation of the CCND2 promoter corresponds with reduced expression of CCND2 mRNA [33]. When we measured mRNA expression and methylation status of CCND2 in HCC patients, and analyzed its correlation with other clinicopathological factors, we found that CCND2 mRNA levels were significantly lower in patients with HCC than in other groups (Figure 2A), whereas the CCND2 methylation rate was higher in HCC patients (Figure 3A, 3B). Thus, downregulation of CCND2 might be due to promoter methylation, and CCND2 is more frequently methylated in HCC than in LC, CHB, and HCs; these data are consistent with those of a previous study [25].

More importantly, CCND2 methylation is closely related to tumor stage in several kinds of human cancer. A recent study of breast cancers found that postmenopausal patients with vascular/lymph invasion exhibit elevated methylation of CCND2 [34]. Another study showed that increased methylation of the CCND2 gene is significantly associated with a higher van Nuys grade and is common in early breast cancer development [35]. Consistent with the results of these studies, we observed that advanced-stage (TNM III/IV) HCC patients had a higher frequency of CCND2 methylation and lower CCND2 mRNA levels than

---

**Figure 3.** Methylation status of CCND2 promoter and correlation with expression of CCND2 mRNA. (A) In total, 55/118 (46.61%) hepatocellular carcinoma (HCC) patients, 8/47 (17.02%) liver cirrhosis (LC) patients, 8/75 (10.67%) chronic hepatitis B (CHB) patients, and 4/35 (11.43%) healthy controls (HCs) exhibited aberrant CCND2 promoter methylation in PBMCs. (B) 52/118 (44.07%) HCC patients, 5/47 (10.64%) LC patients, 7/75 (9.33%) CHB patients, and 2/35 (5.71%) HCs exhibited aberrant CCND2 promoter methylation in plasma. (C) CCND2 mRNA levels differed significantly between the methylation group and non-methylation groups (P<0.005). (D) Representative measurements of CCND2 promoter by methylation-specific polymerase chain reaction (MSP). PC – positive control; WB – water blank; M – methylated sequence; U – unmethylated sequence.
Table 2. Association between CCND2 methylation status and clinical characteristics of HCC patients.

| Parameter                  | CCND2 methylation in PBMCs |                          | CCND2 methylation in plasma |                          | P-value | P-value |
|----------------------------|-----------------------------|--------------------------|-----------------------------|--------------------------|---------|---------|
|                            | Methylation, n (%) | No methylation, n (%)   | Methylation, n (%) | No methylation, n (%) |         |         |
| Age (years)                |                             |                         |                             |                          | 0.802   | 0.524   |
| ≤60                        | 37 (47.44)                  | 41 (52.56)               | 36 (46.15)                  | 42 (53.85)               |         |         |
| >60                        | 18 (45.00)                  | 22 (55.00)               | 16 (40.00)                  | 24 (60.00)               |         |         |
| Gender                     |                             |                         |                             |                          | 0.516   | 0.573   |
| Male                       | 39 (44.83)                  | 48 (55.17)               | 37 (42.53)                  | 50 (57.44)               |         |         |
| Female                     | 16 (51.61)                  | 15 (48.39)               | 15 (48.39)                  | 16 (51.61)               |         |         |
| HBeAg                      |                             |                         |                             |                          | 0.713   | 0.984   |
| Negative                   | 34 (45.33)                  | 41 (54.67)               | 33 (44.00)                  | 42 (56.00)               |         |         |
| Positive                   | 21 (48.84)                  | 22 (51.16)               | 19 (44.19)                  | 21 (55.81)               |         |         |
| Smoking                    |                             |                         |                             |                          | 0.703   | 0.563   |
| No                         | 26 (44.83)                  | 32 (55.17)               | 24 (41.38)                  | 34 (58.62)               |         |         |
| Yes                        | 29 (48.33)                  | 31 (51.67)               | 28 (46.67)                  | 32 (53.33)               |         |         |
| Alcohol                    |                             |                         |                             |                          | 0.795   | 0.717   |
| No                         | 31 (45.59)                  | 37 (54.41)               | 29 (42.65)                  | 39 (57.35)               |         |         |
| Yes                        | 24 (48.00)                  | 26 (52.00)               | 23 (46.00)                  | 27 (54.00)               |         |         |
|AFP (ng/mL)                 |                             |                         |                             |                          | 0.080   | 0.062   |
| ≤20                        | 28 (56.00)                  | 22 (44.00)               | 27 (54.00)                  | 23 (46.00)               |         |         |
| >20                        | 27 (39.71)                  | 41 (60.29)               | 25 (36.76)                  | 43 (63.24)               |         |         |
| Tumor number               |                             |                         |                             |                          | 0.851   | 0.573   |
| Single                     | 41 (47.13)                  | 46 (52.87)               | 37 (42.53)                  | 50 (57.47)               |         |         |
| Multiple                   | 14 (45.16)                  | 17 (54.84)               | 15 (48.39)                  | 16 (51.61)               |         |         |
| Vascular invasion          |                             |                         |                             |                          | 0.012*  | 0.008*  |
| Negative                   | 24 (36.36)                  | 42 (63.64)               | 22 (33.33)                  | 44 (66.67)               |         |         |
| Positive                   | 31 (59.62)                  | 21 (40.38)               | 30 (57.69)                  | 22 (42.31)               |         |         |
| Tumor size                 |                             |                         |                             |                          | 0.992   | 0.751   |
| ≤5 cm                      | 21 (46.67)                  | 24 (53.33)               | 19 (42.22)                  | 26 (57.78)               |         |         |
| >5 cm                      | 34 (46.58)                  | 39 (53.42)               | 33 (45.21)                  | 40 (54.79)               |         |         |
| Histological grading       |                             |                         |                             |                          | 0.566   | 0.411   |
| Poor                       | 16 (44.44)                  | 20 (55.56)               | 15 (41.67)                  | 21 (58.33)               |         |         |
| Moderate                   | 27 (44.26)                  | 34 (55.74)               | 25 (40.98)                  | 36 (59.02)               |         |         |
| Well                       | 12 (57.14)                  | 9 (42.86)                | 12 (57.14)                  | 9 (42.86)                |         |         |
| TNM staging                |                             |                         |                             |                          | 0.004*  | 0.001*  |
| I/II                       | 26 (36.11)                  | 46 (63.89)               | 23 (31.94)                  | 49 (68.06)               |         |         |
| III/IV                     | 29 (63.04)                  | 17 (36.96)               | 29 (63.04)                  | 17 (36.96)               |         |         |
patients with early-stage disease (TNM I/II; \( P < 0.05 \)), and that the frequency of \( \text{CCND2} \) methylation increased with TNM stage progression (Table 3). The mechanism linking \( \text{CCND2} \) promoter methylation to HCC progression is unclear. One possibility is that methylation reduces the inhibitory effect of \( \text{CCND2} \) on cell proliferation. \( \text{CCND2} \) has been reported to maintain cells in a non-proliferative state [31,32]. Hypermethylation of the \( \text{CCND2} \) promoter might reduce the expression of \( \text{CCND2} \) and thereby weaken its growth-inhibitory effect. Padar et al. found that prostate cancer patients with a high Gleason score have significantly greater methylation of \( \text{CCND2} \), those in the higher \( \text{CCND2} \) methylation group had higher mean PSA values, and

| Parameter | \( \text{CCND2} \) methylation in PBMCs | \( \text{CCND2} \) methylation in plasma |
|-----------|--------------------------------------|-------------------------------------|
|           | Methylation, n (%) | No methylation, n (%) | Methylation, n (%) | No methylation, n (%) |
| CTX staging |                           |                           |                           |                           |
| A         | 29 (41.43) | 41 (58.57) | 28 (40.00) | 42 (60.00) |
| B         | 23 (52.27) | 21 (47.73) | 22 (50.00) | 22 (50.00) |
| C         | 3 (75.00)  | 1 (25.00)  | 2 (50.00)  | 2 (50.00)  |

Table 3. \( \text{CCND2} \) methylation levels in PBMCs and TNM stage from HCC patients.

| Clinicopathological feature | Variable | Number of cases | Methylation | No methylation | Detection rate (%) |
|-----------------------------|----------|----------------|-------------|----------------|--------------------|
| TNM stage                  | I        | 48             | 16          | 32             | 33.33              |
|                            | II       | 24             | 9           | 15             | 37.50              |
|                            | III      | 36             | 23          | 13             | 63.89              |
|                            | IV       | 10             | 7           | 3              | 70.00              |
|                            | Total    | 118            | 55          | 63             | 46.61              |

Table 4. Diagnostic utility of AFP, \( \text{CCND2} \) promoter methylation, and combined measurement for discrimination of HCC from LC and CHB.

\( \text{Se} \) – sensitivity; \( \text{Sp} \) – specificity; \( \text{PPV} \) – positive predictive value; \( \text{NPV} \) – negative predictive value; * significant difference (\( P<0.05 \)).

patients with early-stage disease (TNM I/II; \( P<0.05 \)), and that the frequency of \( \text{CCND2} \) methylation increased with TNM stage progression (Table 3). The mechanism linking \( \text{CCND2} \) promoter methylation to HCC progression is unclear. On possibility is that methylation reduces the inhibitory effect of \( \text{CCND2} \) on cell proliferation. \( \text{CCND2} \) has been reported to maintain cells in a non-proliferative state [31,32]. Hypermethylation of the \( \text{CCND2} \) promoter might reduce the expression of \( \text{CCND2} \) and thereby weaken its growth-inhibitory effect. Padar et al. found that prostate cancer patients with a high Gleason score have significantly greater methylation of \( \text{CCND2} \), those in the higher \( \text{CCND2} \) methylation group had higher mean PSA values, and
CCND2 methylation is associated with clinicopathological features of poor prognosis [36]. Our results, along with the observations cited above, reveal that elevated CCND2 methylation rate is correlated with the progression of HCC, suggesting that altered methylation of the CCND2 promoter might be useful for predicting HCC progression.

Currently, AFP is the biomarker used most widely for HCC screening and diagnosis. However, the sensitivity of serum AFP is only 22–60%, depending on the cut-off point [7,37,38]; consequently, its clinical value is limited. As shown in Figure 5, the rate of HCC detection was significantly higher in the CCND2-methylated group than in the unmethylated group, regardless of whether the AFP concentration was greater than or less than 20 ng/mL. This indicates that CCND2 methylation can compensate for deficiencies of AFP and increase the detection rate of HCC. Relative to AFP alone, combined measurement of both markers significantly increased the sensitivity (P<0.001) and NPV (P<0.05). Although the specificity of combined measurement of CCND2 promoter methylation and AFP levels is low, it could be used as an initial screening tool for HCC due to its high sensitivity in distinguishing HCC from LC and CHB patients, thereby decreasing the number of missed diagnoses; if screening is positive, follow-up tests (such as ultrasound, CT, or MRI) may be needed to assist diagnosis, or follow-up appointments should be more frequent.

![Graphs showing the sensitivity and specificity of combined measurement compared to AFP alone in detecting HCC](Image)
Several studies showed that PBMCs and plasma cell-free DNA are useful for identifying gene mutation and abnormal DNA methylation, and can therefore be used for diagnosis of human cancers [39–41]. In this study, we measured CCND2 methylation status both in PBMCs and plasma, and obtained consistent results from both types of samples. A previous molecular profiling study [42] revealed that HBV and hepatitis C virus (HCV) cause HCC through different carcinogenetic pathways. Hence, to decrease bias caused by different viruses, we investigated the methylation status of CCND2 in a cohort comprising only HBV-infected patients.

One weakness of this study is that the MSP method is a qualitative approach for detecting gene methylation. Other methods, such as direct sequencing, may provide more accurate information about methylation. However, MSP can be performed rapidly and easily, enabling most clinical laboratories to carry it out. Although the results of MSP do not provide complete information, the method can still be used to select methylated subjects that may require further examination by sequencing. PIVKA-II, a prothrombin induced by vitamin K deficiency, is increased in malignant hepatocytes [43], suggesting that it may have potential as a biomarker for HCC. A number of studies have revealed that combined determination of PIVKA-II and AFP can improve the diagnostic accuracy of HCC detection compared with either of these biomarkers alone [44,45]. In the present study, we did not assess the diagnostic value of PIVKA-II alone or in combination with CCND2 methylation in patients with HCC. A future study will be required to address this point.

### Conclusions

Methylation of the CCND2 promoter is common in patients with HCC. Combined measurement of CCND2 methylation plus serum AFP levels increased the diagnostic value of AFP for discrimination of HCC from LC and CHB, indicating that combined detection of CCND2 methylation and AFP has potential as a robust and non-invasive biomarker for diagnosis of HCC. Furthermore, CCND2 promoter methylation was observed more frequently in HCC patients with advanced TNM stage and vascular invasion, suggesting that this marker might be used to predict the progression of HBV-associated HCC.

### Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Medical Ethics Committee of Shandong University Qilu Hospital) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

### Conflict of interest

None.
References:

1. Torre LA, Bray F, Siegel RL et al: Global cancer statistics, 2012. Cancer J Clin, 2015; 65(2): 87–108
2. Zhu RX, Seto WK, Lai CL, Yueen MF: Epidemiology of hepatocellular carcinoma in the Asia-Pacific Region. Gut Liver, 2016; 10(3): 332–39
3. Chen W, Zheng R, Baade PD et al: Cancer statistics in China, 2015. Cancer J Clin, 2016; 66(2): 115–32
4. Fong ZV, Tanabe KK: The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review. Cancer, 2014; 120(18): 2824–38
5. Villanueva A, Minguez B, Forner A et al: Hepatocellular carcinoma: Novel molecular approaches for diagnosis, prognosis, and therapy. Ann Rev Med, 2010; 61: 317–28
6. Huang TS, Shyu YC, Turner R et al: Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: A systematic review and meta-analysis protocol. Syst Rev, 2013; 2: 37
7. Farinati F, Marino D, De Giorgio M et al: Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol, 2006; 101(3): 524–32
8. Forner A, Reig M, Bruix J: Hepatocellular carcinoma. Lancet (London, England), 2018; 391(10127): 1301–14
9. Singal AG, Conjeevaram HS, Volk ML et al: Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarker Prev, 2012; 21(9): 793–99
10. Singal A, Volk ML, Waljee A et al: Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther, 2009; 30(1): 37–47
11. Simmons Q, Fetzer DT, Yokoo T et al: Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther, 2017; 45(1): 169–77
12. Chon YE, Jung KS, Kim MJ et al: Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Clin Pharmacol Ther, 2018; 47(8): 1201–12
13. Omata M, Lesmana LA, Tateishi R et al: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int, 2010; 4(2): 439–74
14. Sundar IK, Yin Q, Baiyer BS et al: DNA methylation profiling in peripheral lung tissues of smokers and patients with COPD. Clin Epigenetics, 2017; 9: 11
15. Wu HC, Southey MC, Hibshoosh H et al: DNA methylation in breast cancer from high-risk women in the breast cancer family registry. Anticancer Res, 2017; 37(2): 659–64
16. Zhang YJ, Wu HC, Shen J et al: Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res, 2007; 13(8): 2378–84
17. Feng Q, Stern JE, Hawes SE et al: DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol, 2010; 88(2): 287–92
18. Nishida N, Arizumi T, Takita M et al: Quantification of tumor DNA in serum by digital PCR. Biol Blood Marrow Transplant, 2011; 17(6): 69–75
19. Li F, Fan YC, Gao S et al: Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma. Genes Chromosomes Cancer, 2014; 53(1): 90–97
20. Wang J, Qin Y, Li B et al: Detection of aberrant promoter methylation of GSTPI in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem, 2006; 39(A): 344–48
21. Sherr CJ: D-type cyclins. Trends Biochem Sci, 1995; 20(5): 187–90
22. Tam SW, Theodoras AM, Shay JW et al: Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: Association with Cdk4 is required for Cyclin D1 function in G1 progression. Oncogene, 1994; 9(9): 2663–74
23. Meyyappan M, Wong H, Hull C, Riabowol KT: Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells. Mol Cell Biol, 1998; 18(6): 3163–72
24. Meyyappan M, Atadja PW, Riabowol KT: Regulation of gene expression and transcription factor binding activity during cellular aging. Biol Signals, 1996; 5(3): 130–38
25. Tsutsui M, Iizuka N, Moribe T et al: Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma. Clin Chim Acta, 2010; 411(7–8): 516–20
26. Evron E, Umbricht CB, Korz D et al: Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res, 2001; 61(6): 2782–87
27. Yu J, Leung WK, Ebert MP et al: Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer. Br J Cancer, 2003; 88(10): 1560–65
28. Hsu A, Wong CP, Yu Z et al: Promoter de-methylation of cyclin D2 by sulforaphane in prostate cancer cells. Clin Epigenetics, 2011; 3(1): 3
29. Mermelstein A, Gerson A, Wallisch S et al: Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer, 2005; 93(3): 338–45
30. Dhillon VS, Shahid M, Husain SA: CpG methylation of the FHT, FANC, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer, 2004; 3: 33
31. Matushabayashi H, Sato N, Fukushima N et al: Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res, 2003; 9(4): 1446–52
32. Tahara T, Arisawa T: DNA methylation as a molecular biomarker in gastric cancer. Epigenetics, 2015; 7(3): 475–86
33. Herrera RI, Costa VL, Cervera N et al: Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl), 2006; 84(11): 911–18
34. Callahan CL, Wang Y, Marian C et al: DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study. Epigenetics, 2016; 11(9): 643–52
35. Lehmann U, Langer F, Feist H et al: Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol, 2002; 160(2): 605–12
36. Padar A, Sathyanarayana Ug, Suzuki M et al: Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res, 2003; 9(13): 4730–43
37. Lok AS, Sterling RK, Everhart JE et al: Des-gamma-carboxyprothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology, 2010; 138(2): 493–502
38. Marrero JA, Feng Z, Wang Y et al: Alpha-fetoprotein, des-gamma-carboxyprothrombin, and lectin-binding alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology, 2009; 137(1): 110–18
39. Terry MB, Delgado-Cruzata L, Vin-Raviv N et al: DNA methylation in white blood cells: Association with risk factors in epidemiologic studies. Epigenetics, 2011; 6(7): 828–37
40. Friso S, Uddali S, Guarinì P et al: Global DNA hypomethylation in peripheral blood mononuclear cells as a biomarker of cancer risk. Cancer Epidemiol Biomarkers Prev, 2013; 22(3): 348–55
41. Pezzuto F, Buonaguro L, Buonaguro FM, Torresello ML: The role of circulating free DNA and microRNA in non-invasive diagnosis of HBV- and HCV-related hepatocellular carcinoma. Int J Mol Sci, 2018; 19(4): 1007
42. Iizuka N, Oka M, Yamada-Okabe H et al: Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res, 2002, 62(14): 3939–44
43. Xing H, Yan C, Cheng L et al: Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma. Tumour Biol, 2016 [Online ahead of print]
44. Wang Q, Chen Q, Zhang X et al: Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol, 2019; 25(36): 5515–29
45. Loglio A, Lavorone M, Facchetti F et al: The combination of PiVKA-II and AFP improves the detection accuracy for HCC in HBV-carcinosis cirrhotics on long-term oral therapy. Liver Int, 2020 [Online ahead of print]